Covid-19: Working with govt to ensure smooth supply of medicines, says IPA

The pharma industry body also said that it is not aware of any medicines shortage, to date

pharma, medicines, drugs
The member companies are closely monitoring orders and inventories of medicines
Press Trust of India New Delhi
2 min read Last Updated : Mar 21 2020 | 10:25 PM IST

The Indian Pharmaceutical Alliance (IPA) on Saturday said it along with its member companies is working with the government, various pharma industry associations in India and other key stakeholders in the pharmaceutical supply chain to ensure that patients in India and the world continue to have access to medicines.

The member companies are closely monitoring orders and inventories of medicines, it said.

"With an adequate stock of Active Pharmaceutical Ingredients (APIs), finished product formulations and channel availability, we would be able to sustain the supply of medicines for the coming months, the IPA said in a statement.

The pharma industry body also said that it is not aware of any medicines shortage, to date.

"We are working closely with the International Generic and Biosimilar Medicines Association (IGPA), World Health Organisation (WHO) headquarters in Switzerland and its India office, Association of Affordable Medicines (AAM) USA, Medicines for Europe and several other country associations to assess international developments and any potential impact on supply of medicines globally," the IPA said.

The IPA and its companies are aligned to government initiatives of containment measures and social distancing while meeting supply commitments in the essential services for availability of medicines, it added.

The IPA is committed to providing quality medicines to patients in India and across globe as patient centricity and welfare is fundamental to us, the statement said.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusIndian Pharmaceuticals Industry

First Published: Mar 21 2020 | 6:04 PM IST

Next Story